Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Wasserman

Showing results (251-260 of 299) with videos related to

Pageof 30
Sort By:
Clinical Cardiology|February 1, 2014
Rationale and design of LAPLACE-2: a phase 3, randomized, double-blind, placebo- and ezetimibe-controlled trial evaluating the efficacy and safety of evolocumab in subjects with hypercholesterolemia on background statin therapyJennifer G Robinson, William J Rogers, Bettina S Nedergaard, et al.
Circulation|November 21, 2013
Efficacy and safety of longer-term administration of evolocumab (AMG 145) in patients with hypercholesterolemia: 52-week results from the Open-Label Study of Long-Term Evaluation Against LDL-C (OSLER) randomized trialMichael J Koren, Robert P Giugliano, Frederick J Raal, et al.
Circulation|July 26, 2013
AMG145, a monoclonal antibody against proprotein convertase subtilisin kexin type 9, significantly reduces lipoprotein(a) in hypercholesterolemic patients receiving statin therapy: an analysis from the LDL-C Assessment with Proprotein Convertase Subtilisin Kexin Type 9 Monoclonal Antibody Inhibition Combined with Statin Therapy (LAPLACE)-Thrombolysis in Myocardial Infarction (TIMI) 57 trialNihar R Desai, Payal Kohli, Robert P Giugliano, et al.
Circulation|January 16, 2008
Randomized double-blind trial of darbepoetin alfa in patients with symptomatic heart failure and anemiaJalal K Ghali, Inder S Anand, William T Abraham, et al.
Journal of the American College of Cardiology|April 4, 2014
Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumabErik Stroes, David Colquhoun, David Sullivan, et al.
Clinical Cardiology|February 17, 2017
Design and rationale of the EBBINGHAUS trial: A phase 3, double-blind, placebo-controlled, multicenter study to assess the effect of evolocumab on cognitive function in patients with clinically evident cardiovascular disease and receiving statin background lipid-lowering therapy-A cognitive study of patients enrolled in the FOURIER trialRobert P Giugliano, Francois Mach, Kenton Zavitz, et al.
The New England Journal of Medicine|March 18, 2017
Evolocumab and Clinical Outcomes in Patients with Cardiovascular DiseaseMarc S Sabatine, Robert P Giugliano, Anthony C Keech, et al.
The Journal of Molecular Diagnostics : JMD|October 24, 2003
Establishment of stably EBV-transformed cell lines from residual clinical blood samples for use in performance evaluation and quality assurance in molecular genetic testingSusan H Bernacki, Ana K Stankovic, Laurina O Williams, et al.
JACC. Heart Failure|December 3, 2014
Safety and tolerability of omecamtiv mecarbil during exercise in patients with ischemic cardiomyopathy and anginaBarry H Greenberg, Willis Chou, Khalil G Saikali, et al.
Stroke|April 22, 2020
Stroke Prevention With the PCSK9 (Proprotein Convertase Subtilisin-Kexin Type 9) Inhibitor Evolocumab Added to Statin in High-Risk Patients With Stable AtherosclerosisRobert P Giugliano, Terje R Pedersen, Jeffrey L Saver, et al.
Pageof 30

Showing results (251-260 of 299) with videos related to

Sort By:
Pageof 30
Clinical Cardiology|February 1, 2014
Rationale and design of LAPLACE-2: a phase 3, randomized, double-blind, placebo- and ezetimibe-controlled trial evaluating the efficacy and safety of evolocumab in subjects with hypercholesterolemia on background statin therapyJennifer G Robinson, William J Rogers, Bettina S Nedergaard, et al.
Circulation|November 21, 2013
Efficacy and safety of longer-term administration of evolocumab (AMG 145) in patients with hypercholesterolemia: 52-week results from the Open-Label Study of Long-Term Evaluation Against LDL-C (OSLER) randomized trialMichael J Koren, Robert P Giugliano, Frederick J Raal, et al.
Circulation|July 26, 2013
AMG145, a monoclonal antibody against proprotein convertase subtilisin kexin type 9, significantly reduces lipoprotein(a) in hypercholesterolemic patients receiving statin therapy: an analysis from the LDL-C Assessment with Proprotein Convertase Subtilisin Kexin Type 9 Monoclonal Antibody Inhibition Combined with Statin Therapy (LAPLACE)-Thrombolysis in Myocardial Infarction (TIMI) 57 trialNihar R Desai, Payal Kohli, Robert P Giugliano, et al.
Circulation|January 16, 2008
Randomized double-blind trial of darbepoetin alfa in patients with symptomatic heart failure and anemiaJalal K Ghali, Inder S Anand, William T Abraham, et al.
Journal of the American College of Cardiology|April 4, 2014
Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumabErik Stroes, David Colquhoun, David Sullivan, et al.
Clinical Cardiology|February 17, 2017
Design and rationale of the EBBINGHAUS trial: A phase 3, double-blind, placebo-controlled, multicenter study to assess the effect of evolocumab on cognitive function in patients with clinically evident cardiovascular disease and receiving statin background lipid-lowering therapy-A cognitive study of patients enrolled in the FOURIER trialRobert P Giugliano, Francois Mach, Kenton Zavitz, et al.
The New England Journal of Medicine|March 18, 2017
Evolocumab and Clinical Outcomes in Patients with Cardiovascular DiseaseMarc S Sabatine, Robert P Giugliano, Anthony C Keech, et al.
The Journal of Molecular Diagnostics : JMD|October 24, 2003
Establishment of stably EBV-transformed cell lines from residual clinical blood samples for use in performance evaluation and quality assurance in molecular genetic testingSusan H Bernacki, Ana K Stankovic, Laurina O Williams, et al.
JACC. Heart Failure|December 3, 2014
Safety and tolerability of omecamtiv mecarbil during exercise in patients with ischemic cardiomyopathy and anginaBarry H Greenberg, Willis Chou, Khalil G Saikali, et al.
Stroke|April 22, 2020
Stroke Prevention With the PCSK9 (Proprotein Convertase Subtilisin-Kexin Type 9) Inhibitor Evolocumab Added to Statin in High-Risk Patients With Stable AtherosclerosisRobert P Giugliano, Terje R Pedersen, Jeffrey L Saver, et al.
Pageof 30